ReviewFrontiers of medicine2018
Complex interplay between tumor microenvironment and cancer therapy.
Review in Frontiers of medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Lactate as a Signaling Molecule in the Tumor Microenvironment: Implications for Cancer Progression.Biochemical genetics · 2026Review
- Common oncogenic mutations in colorectal cancer: drivers of carcinogenesis and potential therapeutic targets.Frontiers in pharmacology · 2026Review
- PPARγ accelerates OSCC progression via Th17 polarization and CEBPA/IL-17C signaling.Journal of cancer research and clinical oncology · 2025Article
- Feasibility and mechanism ofAnnals of nuclear medicine · 2025Article
- Reprogrammed immuno-metabolic environment of cancer: the driving force of ferroptosis resistance.Molecular cancer · 2025Review
- Unveiling vitamin C: A new hope in the treatment of diffuse large B‑cell lymphoma (Review).International journal of oncology · 2025Review
- Uncovering immune cell heterogeneity in hepatocellular carcinoma by combining single-cell RNA sequencing with T-cell receptor sequencing.World journal of hepatology · 2025Article
- Neutrophil heterogeneity and plasticity: unveiling the multifaceted roles in health and disease.MedComm · 2025Review
- A bibliometric visualization of resistance to lung cancer immunotherapy: a decade of research progress (2014-2024).Frontiers in oncology · 2025Article
- Tumor heterogeneity assessment using single-cell RNA sequencing (scRNA-seq): applications in lung cancer for diagnosis and treatment.Frontiers in immunology · 2025Review
- CD74 facilitates immunotherapy response by shaping the tumor microenvironment of hepatocellular carcinoma.Molecular medicine (Cambridge, Mass.) · 2024Article
- Tumor microenvironment and cancer metastasis: molecular mechanisms and therapeutic implications.Frontiers in pharmacology · 2024Review
- A short-term three dimensional culture-based drug sensitivity test is feasible for malignant bone tumors.Human cell · 2023Article
- Multiparametric chemical exchange saturation transfer MRI detects metabolic changes in breast cancer following immunotherapy.Journal of translational medicine · 2023Article
- Cancer associated fibroblast derived gene signature determines cancer subtypes and prognostic model construction in head and neck squamous cell carcinomas.Cancer medicine · 2023Article
- Pirfenidone suppressed triple-negative breast cancer metastasis by inhibiting the activity of the TGF-β/SMAD pathway.Journal of cellular and molecular medicine · 2023Article
- Drug resistance mechanism and reversal strategy in lung cancer immunotherapy.Frontiers in pharmacology · 2023Review
- Differentiation-related genes in tumor-associated macrophages as potential prognostic biomarkers in non-small cell lung cancer.Frontiers in immunology · 2023Article
- Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib.NPJ precision oncology · 2022Article
- Heparanase is a prognostic biomarker independent of tumor purity and hypoxia based on bioinformatics and immunohistochemistry analysis of esophageal squamous cell carcinoma.World journal of surgical oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor microenvironment (TME) is comprised of cellular and non-cellular components that exist within and around the tumor mass. The TME is highly dynamic and its importance in different stages of cancer progression has been well recognized. A growing body of evidence suggests that TME also plays pivotal roles in cancer treatment responses. TME is significantly remodeled upon cancer therapies, and such change either enhances the responses or induces drug resistance. Given the importance of TME in tumor progression and therapy resistance, strategies that remodel TME to improve therapeutic responses are under developing. In this review, we provide an overview of the essential components in TME and the remodeling of TME in response to anti-cancer treatments. We also summarize the strategies that aim to enhance therapeutic efficacy by modulating TME.
Indexed as
Identifiers
30097962What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.